-

Taro to Acquire Alchemee From Galderma

  • Alchemee’s flagship brand Proactiv® is an iconic product synonymous with acne care

ZUG, Switzerland & HAWTHORNE, N.Y.--(BUSINESS WIRE)--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.

 

"We are excited to add Proactiv® to Taro’s broad portfolio of prescription and over-the-
counter dermatology products. We look forward to welcoming the Alchemee team into Taro

and working together to continue to make a difference to the millions of people living with
acne around the world.

 

UDAY BALDOTA
CHIEF EXECUTIVE OFFICER
TARO

 

Proactiv® has been used and trusted by millions around the world for more than 25 years. Originally set up as a subscription-based business, Proactiv® quickly became a leading U.S. consumer acne brand.

 

“We are proud of the work we have done together to serve customers suffering from acne
around the world through Proactiv®. I am confident that Taro is the right owner to build on
Alchemee’s strong foundation. Their vision is aligned to Alchemee, which comes with an
incredible legacy and brand equity, and a great team with a clear plan for future success.”


FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed.

About Alchemee
At Alchemee, we aspire to inspire. We are alchemists at heart, harnessing science to create powerful wellness solutions. The combination of alchemy and “me” offers the right mixture of science, expertise, and support that empowers our customers with confidence. Through one-of-a-kind expert-designed formulas and positive guidance, Alchemee provides solutions that are as effective as they are transformative. At Alchemee, we are committed to empowering the world one person at a time. Alchemee. Transformation beyond expectation. www.alchemee.com

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.

About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

Forward-Looking Statements

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Neither Galderma, Alchemee, nor Taro has any obligation to publicly update or revise any forward-looking statements.

Contacts

Media Contact
Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Director, Global Communications
sebastien.cros@galderma.com
+41 79 529 59 85

Taro
William J. Coote
VP, Chief Financial Officer
(914) 345-9001
William.Coote@taro.com

Galderma Logo
Galderma Logo

Galderma

NYSE:TARO

Release Versions

Contacts

Media Contact
Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Director, Global Communications
sebastien.cros@galderma.com
+41 79 529 59 85

Taro
William J. Coote
VP, Chief Financial Officer
(914) 345-9001
William.Coote@taro.com

Social Media Profiles
More News From Galderma

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the AR...

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.1 With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands.8,10,12,21-31 With three decades of innovation across technology, packaging, and treatment areas, Res...

EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and effi...
Back to Newsroom